Atossa Therapeutics…announced that the U.S. Food and Drug Administration (&#39;FDA&#39;) has granted Rare Pediatric Disease (&#39;RPD&#39;) designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome (&#39;MAS&#39;) in females

Z-endoxifen - Atossa Therap

May 4, 2026